FIELD: medicine; pharmacology.
SUBSTANCE: invention relates to the pyrimidine derivatives with general formula I and their pharmaceutically acceptable salts, which possess tyrosine kinase ZAP-70, FAK and Syk-inhibiting activity, and to their application. The compounds can be used for treatment or prevention of diseases or conditions, where the activation of tyrosine kinase ZAP-70, FAK and/or Syk is involved, e.g., heart failure, chronic obstructive pulmonary disease, Alzheimer's disease et al. In general formula (I) 
, X is for CR0; R0, R1, R2, R3 and R4 - each identifies independently hydrogen; C1-C8alkyl; hydroxyC1-C8 alkyl; or R3 and R4 together with the adjoined nitrogen and carbon atoms create the 5-10-term heterocyclic ring and, besides, contain 1, 2 or 3 heteroatoms, chosen from N, O and S; or R1 , R2 and R3 each identifies independently the halogen; C1-C8alcoxy; hydroxyC1-C8 alcoxy; C1-C8 alcoxy -C1-C8 alcoxy; phenyl; 5-6-term heterocyclic ring; containing 1-4 heteroatoms, chosen from N and O; nitro; carboxy; -N(C1-C8alkyl)C(O)-C1-C8 alkyl; -CONR10R11; -SO2N(R10)R11; where R10 and R11 each identifies independently the hydrogen; hydroxy; C1-C8 alkyl; C2-C8alkenyl; C3-C8cycloalkyl; C3-C8 cycloalkyl -C1-C8 alkyl; C2-C8 alcoxy -C1-C8 alkyl; hydroxy C1-C8 alcoxy -C1-C8 alkyl; hydroxyC1-C8 alkyl; or 5-10-term heterocyclic ring, containing up to two heteroatoms, chosen from N and S; or R1 and R2 together with the adjoined carbon atoms create the aryl or 5-10-term heteroaryl radical, containing one or two heteroatoms, chosen from N, O and S; or R5 and R6 identifies independently from each other the hydrogen; halogen; cyano; C1-C8 alkyl; haloC1-C8alkyl; R7, R8 and R9 identifies independently from each other the hydrogen; hydroxy; C1-C8alkyl; haloC1-C8alkyl; C1-C8alcoxy; -Y-R12, where Y means the simple link or O and R12 means C1-C4alkyl, substituted or unsubstituted 5-, 6- or 7-term heterocyclic ring, containing 1, 2 or 3 heteroatoms, chosen from N, O and S; carboxy; -N(C1-C8 alkyl)-CO-NR10R11; - -N(R10)(R11); R7 and R8 or R8 and R9, correspondingly, together with the adjoined carbon atoms create the 5- or 6-term heteroaryl containing 1, 2 or 3 heteroatoms, chosen from N; or 5- or 6- term carbocyclic ring; or R7 means hydrogen, hydroxyl, C1-C4alkyl, unsubstituted or terminally substituted hydroxyl group; C1-C8alcoxy group, unsubstituted or terminally substituted by hydroxyl, C1-C4 alcoxy group or unsubstituted or substituted C1-C4alkyl 5-6-term heterocyclic ring, containing 1-3 heteroatoms, chosen from N and O; Provided, one R1, R2 or R3 means -CON(R10)R11; or -SO2N(R10)R11.
EFFECT: therapeutic efficiency is increased.
7 cl, 14 tbl, 184 ex
| Title | Year | Author | Number |
|---|---|---|---|
| 2,4-DI(PHENYLAMINO)PYRIMIDINES, APPLIED IN TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNE SYSTEM DISORDERS | 2004 |
|
RU2400477C2 |
| PREPARING STERIC HINDERED AMINE ETHERS | 1999 |
|
RU2224758C2 |
| QUINAZOLINONE DERIVATIVES AND THEIR USE AS AGONISTS OF CANNABINOID (CB) RECEPTOR | 2003 |
|
RU2374235C2 |
| METHOD FOR PREPARING HERBICIDE DERIVATIVES AND INTERMEDIATE COMPOUND | 2000 |
|
RU2244715C2 |
| 2,4-DI(HETERO)ARYLAMINOPYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | 2004 |
|
RU2403251C2 |
| QUINAZOLINE DERIVATIVES EXHIBITING TYROSINE KINASE INHIBITING ACTIVITY | 2006 |
|
RU2414457C2 |
| NOVEL SUBSTITUTED THIOPHENE PYRIMIDINONE DERIVATIVES AS 17β HYDROXYSTEROID DEHYDROGENASE INHIBITORS | 2004 |
|
RU2409581C2 |
| 3,4-SUBSTITUTED 1H-PIRAZOLE COMPOUNDS AND THEIR APPLICATION AS CYCLIN-DEPENDANT KINASES (CDK) AND MODULATORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) | 2004 |
|
RU2408585C2 |
| PHENYL DERIVATIVES AS PPAR AGONISTS | 2004 |
|
RU2374230C2 |
| THIAZOLYL DIHYDROQUINAZOLINES | 2007 |
|
RU2430923C2 |
